Response to ASX Aware Letter

• LTR Pharma confirms the binding agreement was signed on June 8, 2026
• Company announced the agreement pre-market on June 9, 2026
• LTR Pharma relied on Listing Rule 3.1A for not disclosing earlier
• The company is in compliance with ASX Listing Rules
• Board authorized the responses to the ASX query letter

LTR Pharma Ltd has responded to the Australian Securities Exchange (ASX) query letter regarding the timing of their announcement about a binding agreement with Shed Holdings LLC for the distribution of ROXUS in the United States. The company confirms that the binding agreement was signed and exchanged on June 8, 2026, and was announced pre-market on June 9, 2026. LTR Pharma relied on Listing Rule 3.1A, which exempts certain information from immediate disclosure, as the agreement was still in negotiation. The company maintains that it was in compliance with ASX Listing Rules and that the responses have been authorized and approved by the Board.